2023年IAC颈动脉狭窄解读标准对治疗阈值的影响
本研究评估采用2023年IAC推荐的标准(PSV>230 cm/s)解读颈动脉重度狭窄对分类的影响。单中心回顾性分析1038例患者3141条ICA,与实验室原阈值PSV>275 cm/s相比,≥70%狭窄的检出数量增加52%。但联合EDV>100 cm/s和ICA/CCA比值>4后,差异无统计学意义。
要点
- 采用IAC PSV>230 cm/s阈值使≥70%狭窄的ICA数量增加52%。
- 联合EDV和ICA/CCA比值可消除因阈值改变导致的分类差异。
- 多参数评估对颈动脉狭窄的准确分级至关重要。
核心结论
- 采用IAC推荐的PSV>230 cm/s阈值使更多ICA从<70%重新分类为≥70%狭窄,可能影响患者管理。
- 联合EDV>100 cm/s和ICA/CCA比值>4可消除因阈值改变导致的显著分类差异。
研究设计与样本
- 单中心回顾性研究,纳入2021年7月至2023年6月在IAC认证门诊血管实验室接受CDU的患者。
- 共分析1038例患者的3141条ICA。
主要发现
- 采用PSV>230 cm/s阈值,≥70%狭窄的ICA数量为406条,而实验室阈值PSV>275 cm/s为266条,增加52%(P<.0001)。
- 仅加ICA/CCA比值>4时,≥70%狭窄数量为206 vs 176,差异17%(P<.0001)。
- 仅加EDV>100 cm/s时,≥70%狭窄数量为116 vs 114,差异1.8%(P=.157),无统计学意义。
- 同时加EDV>100 cm/s和ICA/CCA比值>4时,≥70%狭窄数量为92 vs 91,差异1.1%(P=.317)。
- 男性和女性在两种阈值下≥70%狭窄的比例无显著差异。
关键数值与推荐
- 2023年IAC推荐PSV>230 cm/s作为解读ICA≥70%狭窄的主要参数。
- 本实验室原阈值为PSV>275 cm/s。
- 联合EDV>100 cm/s和ICA/CCA比值>4后,两种阈值下≥70%狭窄数量无显著差异。
临床怎么用
- 临床解读颈动脉CDU时应综合PSV、EDV和ICA/CCA比值等多参数评估狭窄程度。
- 采用IAC新阈值可能增加≥70%狭窄的检出,需结合多参数避免过度分类。
局限性
- 单中心回顾性研究,结果可能受特定患者人群和实验室操作影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In 2023, the Intersocietal Accreditation Commission (IAC) released recommendations to standardize carotid duplex ultrasound (CDU) interpretation among all noninvasive vascular laboratories. Peak systolic velocity (PSV) was recommended as the primary parameter to interpret degree of internal carotid artery (ICA) stenosis, with the threshold for ≥70% ICA stenosis of PSV >230 cm/s. Our study evaluated the impact of adopting these updated IAC criteria for interpretation of high-grade carotid artery stenosis. METHODS: We performed a single-center retrospective study of patients who underwent CDU from July 2021 to June 2023 at an IAC-accredited outpatient vascular laboratory. PSV, end-diastolic velocity (EDV), and ICA/common carotid artery (CCA) ratio were obtained for each ICA examined. The primary outcome was the proportion of ICAs with ≥70% stenosis using PSV of >230 cm/s compared with our laboratory threshold of >275 cm/s. ICAs were then analyzed incorporating EDV and ICA/CCA ratio and compared with interpretations using PSV alone. For generalizability, the number of ICAs from our patient dataset categorized as ≥70% stenosis based on >230 cm/s was compared with published PSV thresholds in 10 cm/s increments to determine at what point these changes in proportion became significantly different. RESULTS: A total of 3141 ICAs were analyzed from 1038 patients. Adopting the IAC-recommended threshold resulted in a 52% increase in those categorized as ≥70% (266 vs 406; P < .0001) compared with our vascular laboratory PSV threshold. Adding ICA/CCA ratio >4 to the PSV criteria, this difference was 17% (176 vs 206; P < .0001). Adding EDV >100 cm/s to the PSV criterion, the increase was only 1.8% and no longer significant (114 vs 116; P = .157). Finally, adding both EDV >100 cm/s and ICA/CCA ratio >4 to the PSV criterion, the increase was 1.1% (91 vs 92; P = .317). There were no significant differences between women and men in the proportion with ≥70% stenosis at either threshold. Based on published PSV ranges from 150 to 360 cm/s, a total of 857 ICAs were identified as having ≥70% stenosis. Significant numbers of ICAs changed category for PSV thresholds of ≤220 or ≥240 cm/s, compared with the number of ICAs using 230 cm/s. CONCLUSIONS: This study demonstrated differences in interpretation for ≥70% ICA stenosis using the updated IAC guideline of PSV >230 cm/s as the primary parameter compared with our laboratory value of 275 cm/s. A significant number of patients would change categorization from <70% to ≥70% stenosis, potentially leading to differences in patient management. However, inclusion of EDV and ICA/CCA ratio mitigated any statistically significant difference in the number of patients recategorized, and demonstrated the importance of multiple parameters in CDU interpretation.
引用
- Kawahara M, Long GW, Bove PG, et al. Impact of 2023 updated Intersocietal Accreditation Commission interpretation criteria for carotid stenosis on thresholds for treatment of carotid artery disease. J Vasc Surg. 2026. PMID: 42285182. doi:10.1016/j.jvs.2026.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。